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Summary The c-MET proto-oncogene encodes the receptor for the Hepatocyte Growth Factor/Scatter
Factor, which is known to mediate mitogenic, motogenic and invasive responses of several cell types. We have
analysed by immunohistochemistry and biochemically the expression of c-MET in benign and malignant
melanocytic lesions. The Met/HGF receptor which in the melanocytic lineage displays the structural features
of the authentic receptor was undetectable in tissue melanocytes and in nevocytic nevi. Only four out of 23
primary melanomas scored positive. Expression was increased to a significant level in 17 out of the 44
metastatic lesions examined. The c-MET expression was homogeneous in multiple metastases from the same
patients. Comparative analyses showed both lack of correlation with the expression of the tumour progression
associated ICAM-1 adhesion molecule and, in 23% of cases, co-expression with the c-KIT encoded receptor.
These findings show that the c-MET gene is expressed at late stages of melanoma progression and suggest that
the presence of Met/HGF receptor may contribute to the acquisition of an invasive phenotype.
The c-MET proto-oncogene encodes a transmembrane tyro-
sine kinase identified as the receptor for a polypeptide known
as Hepatocyte Growth Factor (HGF) (Bottaro et al., 1991;
Naldini et al., 1991a; Naldini et al., 1991b). HGF (Miyazawa
et al., 1989; Nakamura et al., 1989; Zarnegar et al., 1989) is
indistinguishable from Scatter Factor (SF), originally
identified as a powerful polypeptide factor stimulating
epithelial cell motility (Stoker et al., 1987; Weidner et al.,
1990; Gherardi et al., 1989). HGF/SF has been shown to
exert a pleiotropic activity on several cell types mainly of
epithelial origin. It is a powerful mitogen for hepatocytes
both in vitro and in vivo (for a review see Gherardi and
Stoker, 1991) and stimulates the growth in vitro of several
other other epithelial cells, including kidney tubular cells,
keratinocytes and endothelial cells (Kan et al., 1991; Bus-
solino et al., 1992; Rosen et al., 1990; Rubin et al., 1991).
Interestingly, HGF/SF is a powerful inducer of epithelial cell
dissociation, able to increase their motility and invasiveness
(Weidner et al., 1990). A role of HGF/SF and its receptor in
promoting growth of tumour cells and/or in influencing their
metastatic behaviour has been proposed (for a review see
Comoglio, 1993). It has been recently shown that the MET
encoded HGF/SF receptor is overexpressed in carcinomas of
the GI tract (Di Renzo et al., 1991) and in thyroid car-
cinomas belonging to clinically and histologically advanced
subtypes (Di Renzo et al., 1992). All this pointed to the
involvement of HGF/SF and its receptor in the progression
of tumour cells to a more malignant phenotype.
HGF/SF has'been found to be mitogenic for melanocytes
in primary cultures, mainly in the presence of synergistic
factors (Matsumoto et al., 1991; Rubin et al., 1991; Halaban
et al., 1992) and its receptor has been detected in human
melanocytes and melanomas grown in vitro (Kan et al., 1991;
Halaban et al., 1992). In this paper, we studied the expres-
sion of the Met/HGF receptor in the natural history of
human melanocytic lesions, by examining benign nevi,
primary melanomas and metastases. We show that the ex-
pression of immunologically detectable Met/HGF receptor
increases, with significant incidence (39%), in metastatic
lesions, suggesting a correlation with the progression of
melanoma.
Material and methods
Tissue specimens and cell lines
Surgical biopsies of benign, malignant primary and metas-
tatic melanocytic lesions were obtained from the Surgical
Pathology section of the Regina Elena Cancer Institute. Tis-
sue samples were snap frozen in liquid nitrogen. From each
specimen 4 gm cryostat sections were obtained which were
fixed in absolute acetone for 10 min. Fixed sections were
either immediately used in immunohistochemical assays or
kept frozen at - 70°C with no loss of serological activity.
Fixed sections stained with 1% toluidine blue were used to
evaluate the histological features of the lesions. Tumour
thickness was evaluated according to Breslow (1970).
Primary cultures of cutaneous melanocytes were obtained
from Clonetics (San Diego, USA). Cytospins were prepared
using a Shandon cytocentrifuge (Runcorn, Cheshire, UK).
Monoclonal antibodies
The murine monoclonal antibody DQ13 against the a chain
of Met/HGF receptor (Prat et al., 1991a) was raised against
a peptide corresponding to nineteen c-terminal amino acids
(from Ser'372 to Ser'39) of the c-Met sequence, EMBL Data-
Bank reference n X54559. The murine moAb D024 to an
epitope of the extracellular domain of the c-met gene product
was produced using the human gastric carcinoma cell line
GTL-16 as immunogen (Prat et al., 1991b). MoAb 84hlO to
the intercellular adhesion molecule ICAM-1 was obtained
from Immunotech, Marseille, France. MoAb to the extracel-
lular domain of the c-kit receptor was purchased from Boeh-
ringer Mannheim.
Serological assays
The immunohistochemical analysis employed MoAb D024
as purified reagents (Russo et al., 1983) at concentrations
ranging from 10 to 50 jig ml-'. The indirect immunoperox-
idase stain was performed with commercially available
reagents (Vectastain Elite, Burlingame, Ca. USA). Slides
were incubated overnight with MoAb at 4'C in a moist
chamber. The enzymatic activity was developed using 3-
amino-9-ethylcarbazole (AEC) as chromogenic substrate for
8 min. Slides were then rinsed with phosphate buffered saline
and counterstained with Mayer's hematoxylin. Sections on
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which the incubation of the primary antibody was omitted
were used as control.
Western Blotting
Surgical biopsies immediately frozen in liquid nitrogen were
pulverised using a Mikro-Dismembrator TM (B-Braun) in
the presence of liquid nitrogen. Powdered tissues were
solubilised in boiling Laemmli buffer (Laemmli, 1970), con-
taining the reducing agent P-mercaptoethanol. Four hundred
lag of proteins were loaded on each lane. Western blot
analysis was carried out as described by Towbin et al. (1979).
Bound antibodies were revealed with rabbit anti-mouse
antibodies labelled with HR Peroxidase according to the
enhanced chemiluminescence method (ECLTM, Amersham).
Results
Table I shows the list of melanocytic samples examined by
immunohistochemistry. Cultured melanocytes, nevus cells of
intra-dermal and junctional nevi were not labelled by the
monoclonal antibody directed against the extracellular
domain of the MET/HGF receptor (Figure la). In the same
biopsies MoAb D024 stained with variable intensity the
keratinocytes of the basal layer as well as melanophages.
Similarly the receptor was not histochemically detectable in
the majority of primary tumours (Table I). However four
lesions were scored positive, showing either a homogenous-
weak staining or an irregular distribution of the antigen. The
four positive tumours displayed a high degree of dermal
invasiveness (Figure lb). For comparison the pattern of exp-
ression in the same lesions of the ICAM-1 molecule which is
known to be associated with increasing tumour invasiveness
(Natali et al., 1990) is reported (Table II). Positive staining
with the ICAM-1 monoclonal antibody was observed with
the expected distribution without a significant correlation
with the expression of the MET/HGF receptor. In contrast
to primary tumours 17 out of 44 (39%) metastatic foci
collected from different body sites, showed a positive staining
with an apparent lower incidence in parenchymal metastases.
The intensity of the stain was generally weak and only in a
minority of the instances was homogenously distributed in
the metastatic cell population (Figure 1c). Evaluation in four
patients of individual concomitant metastases (Table III)
showed that the expression of the gene product is rather
consistent among autologous lesions. Because the expression
of the c-kit receptor for Stem Cell Factor (SCF) has been
shown to be downregulated in human melanocytes following
malignant transformation (Natali et al., 1992) a comparative
analysis of the c-met and c-kit products in 16 unselected
metastatic lesions was performed. The results reported on
Table IV demonstrated that the two receptor are uncoor-
dinately expressed with only 20% of the samples displaying
detectable levels of both molecules. Furthermore no relation-
Table I Immunohistochemical detection of Met/HGF receptor in
benign and malignant lesions of the melanocyte lineage
Melanocytes (primary cultures) neg.
Intradermal-junctional nevi 0/15a
Blue nevi (simple and cellular type) 0/5
Primary melanomas:
melanoma in situ 0/3
melanoma from superficial spreading 3/12
nodular melanoma 1/6
acral lentiginous melanoma 0/2
total 4/23
Metastatic melanomas:
lymphonodal 13/33
cutaneous 3/7
parenchymal 1/4
total 17/44
aNo. positive/no. tested.
b
Figure 1 Expression of Met/HGF receptor in melanocyte lesions
as revealed by indirect avidin/biotin immunoperoxidase employ-
ing MoAb D024 on 4 ,u acetone fixed cryostat sections. No
detectable levels of the receptor are expressed by nevus cells of an
intra-dermal nevus (asterisk). A weak stain is present in basal
keratinocytes (arrow) a. Melanoma cells and melanophages
(arrows) of a primary melanoma display variable levels of
immunoreactivity b. The immunoreactivity of the latter cells is
partially shadowed by the melanin pigment. The receptor is
homogenously expressed in a case of metastatic melanoma c.
(a-c: x 200).
ship was found between expression of c-met and degree of
pigmentation. In order to investigate the molecular structure
of the c-met receptor expressed by melanoma cells, selected
biopsies expressing different levels of c-met were also
analysed by Western blotting employing MoAb DQ13 against
the COOH-terminal tail of the human protein. Figure 2
shows that the MET/HGF receptor of melanocytic lesions
has structural features of the authentic receptor. The levels of
expression of the MET/HGF receptor detected in Western
blot analysis corresponded to those detected by immuno-
histochemistry.
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Table II Immunohistochemical detection of Met/HGF receptor and
ICAM-1 adhesion molecule in primary melanomas of increasing
dermal invasiveness
Histotypea
Case (thickness: mm) MET receptorb ICAM_lb
BA MSS (1.0) - var
TI MSS (1.5) -
PO MSS (1.9) - var
OR MSS (2.0) - is
CA MSS (2.0) -
DN MSS (2.0) - var
CF NM (2.7) - +
AL NM (3.2) -
GI NM (3.2) - +
BE NM (4.0) - var
OP NM (4.5) var var
BO MSS (4.5) + var
PR MSS (4.5) + is
TA ALM (4.5) - +
BY NM (5.0) - +
Fl MSS (6.0) +
PL ALM (>6.0) - +
aMSS: melanoma from superficial spreading, NM: nodular
melanoma, ALM: acral lentiginous melanoma. b_: no stain, :
homogenous weak stain, +: homogeneous stain, var: stain of
variable intensity from negative to positive, is: isolated areas stained
accounting for less than 20% of the lesion.
Table III Immunohistochemical detection of Met/HGF receptor in
concomitant autologous lymphonodal melanoma metastases
Patient MET receptor
PI Metastasis no. 1 neg.
Metastasis no. 2 neg.
Metastasis no. 3 neg.
PA Metastasis no. 1 var
Metastasis no. 2 var
Metastasis no. 3 var
Metastasis no. 4 var
BI Metastasis no. I neg.
Metastasis no. 2 neg.
Metastasis no. 3 neg.
IA Metastasis no. 1 var
Metastasis no. 2 var
neg: no stain, var: stain of variable intensity.
*4E p145met3
a b C
Figure 2 Western blot analysis of metastatic melanomas
classified by immunohistochemistry as positive a, and negative b:
lane c contains an extract of the human lung carcinoma cell line
A549 expressing the Met/HGF receptor used as control. The
receptor expressed in the positive metastatic lesion has the struc-
tural features of the authentic receptor. The levels of expression
of the receptor correspond to those detected by immunohisto-
chemistry. The arrow indicates the 145 kDa chain of the Met/
HGF receptor.
Discussion
HGF and SF had been originally identified independently as
molecules mediating hepatocyte proliferation (Zarnegar et al.,
1989; Miyazawa et al., 1989; Nakamura et al., 1989) and
epithelial cell motility and invasion (Stoker et al., 1987;
Weidner et al., 1990), respectively. Recently, HGF and SF
have been shown to be identical molecules and indistin-
guishable ligands for the same cMET-encoded receptor,
which mediates both mitogenic and motogenic activities
(Naldini et al., 1991a; Weidner et al., 1990). A role for
HGF/SF and its receptor has been postulated in the acquisi-
tion by tumour cells of an invasive phenotype. In this paper
we have examined benign and malignant lesion of
Table IV Immunohistochemical detection of Met/HGF receptor and Kit/SFC
receptor in metastatic melanomas
Patient Site Pigmentationa MET/HGFb KIT/SFCb
1 CEC Lymphnode + var (50%) var (20%)
2 COR Lymphnode - var (50%)
3 COP Lymphnode
4 PAL Subcutis + - +
5 BON Lymphnode + -
6 PET Lymphnode - - var (80%)
7 PIE Subcutis - - var
8 LOM Subcutis + var (30%) var (20%)
9 CAS Lymphnode - var
10 CAR Lymphnode
11 MAN Subcutis + - ++
12 MAY Lymphnode + + - var
13 STE Liver - -
14 ALL Lymphnode + + var +
15 VIN Lymphnode - +
16 SIN Lymphnode - var
a_ absence, ±: scattered, +: weak, + +: intense pigmentation. b_: no stain,
var: staining of variable intensity, +: homogenous stain, + + (%): intense stain
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melanocyte lineage, showing that a consistent fraction of
metastatic melanomas displays an increased level of expres-
sion of the MET/HGF receptor.
By immunohistochemistry employing MoAbs against the
extracellular domain of the protein, the receptor was
undetectable in melanocytes in benign nevic lesions and in
the majority of the primary melanomas of increasing dermal
invasiveness. Its role in the control of proliferation of
melanocytes and primary melanomas cannot be excluded,
since very low levels of the receptor (120 molecules/cell)
(Matsumoto et al., 1991) below the sensitivity of the
immunohistochemical assay may be expressed in some
lesions. The positive control stain of keratinocytes and of
melanophages in the same tissue samples demonstrated that
the receptor can be detected immunohistochemically when
expressed at a higher level. Despite the low levels of receptor,
MET/HGF has been shown to promote proliferation and
motility in normal melanocytes as well as to maintain high
levels of tyrosinase activity i.e. pigmentation (Halaban et al.,
1992). We have shown that increased expression of the MET/
HGF occurs in a significant fraction of metastatic melanoma,
but without correlation with the degree of pigmentation, thus
indicating that this control function of c-met may be
impaired in metastatic cells.
The rather homogenous expression of the receptor in mul-
tiple autologous metastases suggests that during tumour pro-
gression a selection of a melanoma cell subpopulation with a
constitutive capacity to synthetise the receptor may occur,
thus conferring a potential drive to metastatise. While per se
motogenic, MET/HGF is mitogenic in the presence of syner-
gistic factors such as bFGF and SCF (Halaban et al., 1992).
The demonstration in our study of the uncoordinated expres-
sion of c-met and c-kit as well as the lack of correlation of
c-met expression and anatomical sites of the metastases (i.e.
stromal relationship), suggest that the MET/HGF receptor
may deliver mainly a motogenic stimulus to melanoma cells.
It must be recalled in this context that the expression of a
functional MET/HGF receptor has been shown to be
sufficient to confer on cells an invasive phenotype. In
presence of HGF/SF, NIH-3T3 fibroblasts, transfected with
the cMET proto-oncogene, are prompted to invade collagen
matrices and to migrate in Boyden chambers (Giordano et
al., 1993). HGF/SF is widely distributed in tissues, bound to
the extracellular matrix mainly in the precursor form (pro-
HGF) activated by the widespread urokinase-e-type plas-
minogen activator (Naldini et al., 1992). A paracrine interac-
tion may therefore be envisaged. The limiting step for
melanoma progression towards the metastatic phenotype
may thus be, in some instances, the expression of the Metl
HGF receptor.
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